Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta

Relationship Marketing Study Shows Breaks Down Online Drug Convo
Ambien is a huger seller and has a massive presence online, as affirmed by a study from new media agency Razorfish measuring social influence marketing—the strength that peer influencers have on different brands—across several industries.
The brands in the study were given a social influence marketing (SIM) score that measured two attributes—the total share of consumer conversations a brand has online (share of voice), and the degree to which consumers like or dislike a brand (net sentiment). The SIM score combines the two attributes to measure the favorable impact of a brand.
In the pharmaceutical category, Razorfish measured the SIM scores of the top five brands with the most consumer media spend in 2008: Ambien, Lipitor, Lunesta, Plavix, and Rozerem. Of the five medications, Ambien captured a majority share of voice at 58.8 percent. However, its net sentiment was one percent lower than Lunesta, which received 64 percent net sentiment (but only 9.3 percent share of voice).
“We did conversation monitoring with our partner, TNS Cymfony, and we [analyzed] the online conversation for the last six months of 2008,†said Lisa Flaiz, vice president, group director, national pharma practice lead at Razorfish. “We then established a benchmark index for each industry using the brands we chose to analyze.â€
The data does not include conversations that are not publically viewable, such as forums that require registration or private Facebook accounts. However, that still leaves a ton of data from sources like Twitter, YouTube, and comments on blogs.
“The beauty and the curse of these open forums is that you give up control of the brand, and you have to be willing to accept that there will be some negative comments for the greater good of elevating the conversation around the disease state,†said Flaiz. “Elevating the conversation online is now [like a] funnel—it helps create awareness and preference and I think we can be encourage by this.â€
Interestingly, Rozerem’s reputedly popular Abe Lincoln ads do not show much traction online, with only 0.6 percent share of voice and a total score of 0.5. That can’t feel good from a campaign that cost Takeda $91 million in 2007.
“That’s share of voice over the total industry conversation,†Flaiz pointed out. “From a volume perspective, you just aren’t seeing that much traction in conversation around Rozerem. I think most of the conversation around the beaver came from industry people.â€